Scroll

rabeprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiulcer, benzimidazole derivatives	2350	117976-89-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sodium rabeprazole rabeprazole rabeprazole sodium habeprazole aciphex rabeprazole sodium salt	A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Molecular weight: 359.44 Formula: C18H21N3O3S CLOGP: 2.08 LIPINSKI: 0 HAC: 6 HDO: 1 TPSA: 77.10 ALOGS: -3.03 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

sodium rabeprazole
rabeprazole
rabeprazole sodium
habeprazole
aciphex
rabeprazole sodium salt

A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Molecular weight: 359.44
Formula: C18H21N3O3S
CLOGP: 2.08
LIPINSKI: 0
HAC: 6
HDO: 1
TPSA: 77.10
ALOGS: -3.03
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	52 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	4 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.50 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	1 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.22 L/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 19, 1999	FDA	EISAI INC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Obstructive airways disorder	228.73	9.95	177	61328	20522	63406995
Eosinophilic bronchitis	221.56	9.95	60	61445	513	63427004
Eosinophil count increased	216.84	9.95	134	61371	10794	63416723
Pemphigus	159.05	9.95	4	61501	183722	63243795
Reversible airways obstruction	145.73	9.95	58	61447	1784	63425733
Vital capacity decreased	142.27	9.95	56	61449	1672	63425845
Sputum culture positive	136.62	9.95	58	61447	2109	63425408
Maternal exposure during pregnancy	134.89	9.95	25	61480	220037	63207480
Bronchial secretion retention	125.98	9.95	59	61446	2714	63424803
Neutrophilia	116.30	9.95	65	61440	4341	63423176

Showing 1 to 10 of 259 entries

Previous1 2 3 4 5…26Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	135.80	10.76	249	37571	65033	34854078
Hepatic function abnormal	123.85	10.76	193	37627	44170	34874941
Coombs positive haemolytic anaemia	113.94	10.76	42	37778	930	34918181
Needle fatigue	99.35	10.76	37	37783	844	34918267
Toxicity to various agents	96.78	10.76	48	37772	200314	34718797
Relapsing-remitting multiple sclerosis	93.04	10.76	37	37783	1013	34918098
Gait spastic	91.50	10.76	37	37783	1059	34918052
Lymphadenitis	87.16	10.76	43	37777	1985	34917126
Hypertonic bladder	84.53	10.76	41	37779	1823	34917288
Completed suicide	75.12	10.76	9	37811	98159	34820952

Showing 1 to 10 of 166 entries

Previous1 2 3 4 5…17Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	182.41	9.71	384	84809	112216	79546979
Hepatic function abnormal	178.09	9.71	297	84896	72810	79586385
Completed suicide	169.99	9.71	29	85164	245738	79413457
Toxicity to various agents	164.47	9.71	126	85067	421414	79237781
Obstructive airways disorder	132.85	9.71	166	85027	31293	79627902
Vital capacity decreased	124.26	9.71	53	85140	1763	79657432
Reversible airways obstruction	121.35	9.71	55	85138	2121	79657074
Drug abuse	119.79	9.71	16	85177	162675	79496520
Hypertonic bladder	113.25	9.71	65	85128	4136	79655059
Coombs positive haemolytic anaemia	108.29	9.71	42	85151	1088	79658107

Showing 1 to 10 of 326 entries

Previous1 2 3 4 5…33Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A02BC04	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors
ATC	A02BC54	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors
ATC	A02BD12	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori
ATC	A02BD13	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori
CHEBI has role	CHEBI:49200	proton pump inhibitors
CHEBI has role	CHEBI:49201	anti-ulcer drugs
FDA EPC	N0000175525	Proton Pump Inhibitor
FDA MoA	N0000000147	Proton Pump Inhibitors
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D004791	Enzyme Inhibitors

Showing 1 to 10 of 12 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Duodenal ulcer disease	indication	51868009	DOID:1724
Zollinger-Ellison syndrome	indication	53132006	DOID:0050782
Multiple endocrine adenomas	indication	60549007
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Systemic mast cell disease	indication	397016004	DOID:349
Duodenal Ulcer due to H. Pylori	indication
Maintenance of Healing Gastroesophageal Reflux	indication
Pathological Gastric Hypersecretory Condition	indication
Upper gastrointestinal hemorrhage	off-label use	37372002

Showing 1 to 10 of 15 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.23	acidic
pKa2	3.9	Basic
pKa3	2.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Potassium-transporting ATPase	Transporter	P20648 P51164	ATP4A_HUMAN ATP4B_HUMAN	INHIBITOR			CHEMBL	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.10	DRUG MATRIX
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.12	WOMBAT-PK
Sodium/potassium-transporting ATPase subunit alpha-1	Transporter	P05023	AT1A1_HUMAN				WOMBAT-PK
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.74	DRUG MATRIX
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	5.07	CHEMBL
Fatty acid synthase	Enzyme	P49327	FAS_HUMAN		Ki	5.23	CHEMBL
Insulin-degrading enzyme	Enzyme	P14735	IDE_HUMAN		IC50	4.96	CHEMBL
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	Enzyme	O94760	DDAH1_HUMAN		IC50	4.28	CHEMBL
Cytosolic endo-beta-N-acetylglucosaminidase	Enzyme	Q8NFI3	ENASE_HUMAN		IC50	5.35	CHEMBL

Showing 1 to 10 of 12 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
RZX	PDB_CHEM_ID
007680	NDDF
007681	NDDF
114979	RXNORM
117976-90-6	SECONDARY_CAS_RN
206957	MMSL
31277	MMSL
32828355LL	UNII
387013009	SNOMEDCT_US
4021174	VUID

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Aciphex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4185	TABLET, DELAYED RELEASE	20 mg	ORAL	NDA	28 sections
Rabeprazole sodium	HUMAN PRESCRIPTION DRUG LABEL	1	13668-107	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	28 sections
Rabeprazole sodium	HUMAN PRESCRIPTION DRUG LABEL	1	13668-107	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	28 sections
Rabeprazole sodium	HUMAN PRESCRIPTION DRUG LABEL	1	13668-107	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	28 sections
Rabeprazole sodium	HUMAN PRESCRIPTION DRUG LABEL	1	13668-107	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	28 sections
Rabeprazole Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42291-722	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	31 sections
Rabeprazole Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	45865-123	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	27 sections
RABEPRAZOLE SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	45865-802	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	27 sections
RABEPRAZOLE SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1424	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	27 sections
Rabeprazole Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3145	TABLET, DELAYED RELEASE	20 mg	ORAL	ANDA	29 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next